Abstracts Book - IMRC 2018

• SB6-P107
FABRICATION AND STUDY OF CURCUMIN LOADED
NANOPARTICLES BASED ON PCL FOR SCA7 TREATMENT
María Luisa Del Prado Audelo 1,2 , María Cristina Piña Barba 3 , Jonathan Javier Magaña Aguirre 4 ,
Gerardo Leyva Gómez 5 , David Quintanar Gerrero 1
1 Facultad de Estudios Superiores Cuautitlán, UNAM., Ingeniería y Tecnología, Mexico. 2 Facultad
de Química, UNAM, Pharmacy, Mexico. 3 Instituto de Investigaciones en Materiales, Metálicos y
Cerámicos, Mexico. 4 Instituto Nacional de Rehabilitacion, Genética y genómica, Mexico.
5 Facultad de Química, UNAM, Farmacia, Mexico.
The spinocerebellar ataxias (SCAs) are a large and diverse group of autosomaldominant,
progressive neurodegenerative diseases. They share the clinical
feature of progressive ataxia, reflecting degeneration of the cerebellum and,
often, other connected regions of the nervous system (plyglutamine spino). The
most common SCAs are caused by expansion of a CAG nucleotide repeat that
encodes polyglutamine (polyQ) in the relevant disease proteins.
Spinocerebellar ataxia type 7 (SCA7) is unique among CAG / polyglutamine
(polyQ) repeat diseases due to dramatic intergenerational instability in repeat
length and an associated cone-rod dystrophy retinal degeneration phenotype.
SCA7 is caused by a polyQ expansion in the protein ataxin-7.
Emerging insights into the mechanisms underlying polyQ SCAs suggest that
these diseases may be treated through at least two principal therapeutic routes.
The first is to pharmacologically modulate the perturbed cerebellar circuitry, as
a symptomatic or possibly disease-modifying therapy. The second is to reduce
levels of toxic disease-gene products.
However, the therapeutic effects of drugs are very limited, but often causing
systemic side effects, because almost all large molecule drugs and more than
98% small molecule candidate drugs are unable to reach the brain tissue due to
their poor permeability across the Blood-brain Barrier.
One promising solution is the employment of polymeric nanoparticles (NPs)
such as ε-polycaprolactone (PCL) NPs as drug carrier. The main of this work is
the elaboration and physicochemical characterization of PCL NPs loaded with
curcumin, wich is a fascinating molecule that has a wide use in medicine for
diseases such as cancer and Alzheimer, to explore the potential of application
as a terapeutic treatment for SCA7.